Fathom Therapeutics develops Microcosmos, a drug design engine that uses proprietary physics-based algorithms and AI to simulate protein dynamics at atomic resolution and enable generative design of small molecules. The platform reportedly accelerates modeling of protein dynamics by 10,000x without compromising accuracy and produces data intended to translate quantum mechanical calculations to measurable cellular outcomes. Microcosmos has guided discovery and optimization across multiple target classes and modalities, including rapid generation of novel degraders that are being optimized for clinical advancement. Fathom has an active internal pipeline, multiple external discovery partnerships, and its lead program has progressed into animal efficacy studies. The company was founded by researchers behind the Anton supercomputer and widely used protein–drug binding software, and its leadership team has collectively advanced 19 drugs to the clinic, including seven FDA-approved medicines. Fathom is headquartered in New York and maintains a second office in Boston.

Total raised

$47M

Funding rounds

1

Latest round

Series A

Latest activity

Apr 2026